Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ACBD5
REST API REST API
Homo sapiens
ACBD5 is differentially expressed in 195 experiments: 91 organism parts: cervix, ovary, ... (89 more);, 82 disease states: normal, breast carcinoma, ... (80 more);, 59 cell types 264 cell lines 179 compound treatments and 47 other conditions.
Synonyms KIAA1996, DKFZp434A2417
Orthologs ACBD5 (Gallus gallus)   ENSCING00000000720 (Ciona intestinalis)   Acbd5 (Rattus norvegicus)   Acbd5 (Mus musculus)   acbd5a (Danio rerio)   acbd5b (Danio rerio)   ACBD5 (Bos taurus)   CG8814 (Drosophila melanogaster)   acbd5 (Xenopus tropicalis)   ACBD5 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term transport, membrane, lipid binding, peroxisomal membrane, intracellular membrane-bounded organelle, peroxisome, integral to membrane, binding, fatty-acyl-CoA binding
UniProt Accession Q5T8D3, Q5T8E0, B7Z2A7
InterPro Term Membrane-associated diazepam binding inhibitor, Acyl-CoA-binding protein, ACBP
Search EB-eye ENSG00000107897
Show more properties
Experimental Factors
organism part

studied in E-GEOD-6573, E-GEOD-13911, E-TABM-130, E-GEOD-17539, E-GEOD-26672, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

cell line

studied in E-GEOD-17482, E-GEOD-19639, E-GEOD-24147, E-GEOD-19480, E-GEOD-14519, ... (21 experiments)

Factor Value U/D Experiments
BT474
2
E-MTAB-37, E-GEOD-10890
CaOv3
2
E-MTAB-37, E-GEOD-20272
HCC1143
2
E-MTAB-37, E-GEOD-10890
HCC1428
2
E-GEOD-19639, E-GEOD-10890
HeLa
2
E-GEOD-20081, E-GEOD-13548
MDA435
2
E-GEOD-20089, E-GEOD-10890
258 more value(s).


cell type

studied in E-GEOD-22373, E-MEXP-1121, E-GEOD-21668, E-GEOD-14924, E-GEOD-13909, ... (30 experiments)

Factor Value U/D Experiments
stromal cell
1
E-GEOD-1460
plasmacytoid dendritic cell
1
E-TABM-34
adipose stem cells derived from adult human donor
1
E-GEOD-20033
hematopoietic
1
E-GEOD-9894
spheroid recovery
1
E-GEOD-4219
activated natural killer cell
1
E-TABM-702
53 more value(s).


disease state

studied in E-GEOD-3307, E-GEOD-16134, E-GEOD-6872, E-GEOD-15960, E-MEXP-2069, ... (40 experiments)

Factor Value U/D Experiments
breast carcinoma
2
E-GEOD-10780, E-MTAB-37
undifferentiated sarcoma
1
E-GEOD-21050
lung atypical carcinoid tumor
1
E-MTAB-37
adenocarcinoma
1
E-MTAB-37
clear cell adenocarcinoma
1
E-MTAB-37
Moderate
1
E-GEOD-22148
76 more value(s).


Compound treatment

studied in E-MTAB-798, E-GEOD-10313, E-GEOD-15205, E-TABM-782, E-GEOD-11428, ... (17 experiments)

Factor Value U/D Experiments
amiodarone 7 micromolar
1
E-MTAB-798
fenofibrate 6 micromolar
1
E-MTAB-798
chlormezanone 50 micromolar
1
E-MTAB-798
sodium lactate 25 millimolar
1
E-GEOD-9649
perhexiline 0.6 micromolar
1
E-MTAB-798
allopurinol 28 micromolar
1
E-MTAB-798
173 more value(s).


RNAi

studied in E-MEXP-1857, E-MEXP-1315

Factor Value U/D Experiments
scrambled control
1
1
E-MEXP-1315
Dharmacon control
1
E-MEXP-1857
H1015 ASCL1 siRNA
1
1
E-MEXP-1857
H938 ASCL1 siRNA
1
1
E-MEXP-1857
APE1 RNAi
1
1
E-MEXP-1315
H1033 ASCL1 siRNA
1
E-MEXP-1857


alive at endpoint
studied in E-GEOD-4922

biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-19480

cancer site
studied in E-GEOD-4271

cell treatment
studied in E-MEXP-1192

clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-12172, E-GEOD-21589, E-GEOD-13355, ... (8 experiments)

clinical treatment
studied in E-GEOD-6532

developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-GEOD-18290

dfs time (months)
studied in E-GEOD-21653

disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-21138, E-GEOD-21887 ... (5 experiments)

environmental stress
studied in E-GEOD-4086

estrogen receptor status
studied in E-GEOD-6532

ethnicity
studied in E-GEOD-23120

genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847 ... (5 experiments)

genotype
studied in E-GEOD-17476, E-GEOD-13911, E-GEOD-9761, E-GEOD-13637, E-TABM-601, ... (7 experiments)

growth condition
studied in E-GEOD-9169, E-MEXP-2657, E-GEOD-20540, E-GEOD-19018, E-MEXP-1230, ... (11 experiments)

histology
studied in E-TABM-234, E-GEOD-9489, E-TABM-276, E-GEOD-10780

immunoprecipitated protein
studied in E-GEOD-21918

individual
studied in E-TABM-325, E-TABM-176, E-TABM-740, E-GEOD-19330, E-TABM-666, ... (17 experiments)

Infection
studied in E-GEOD-8527, E-GEOD-13637, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (6 experiments)

injury
studied in E-GEOD-19743

lymph node status
studied in E-GEOD-6532

material type
studied in E-GEOD-9171

media
studied in E-MEXP-765

metastasis
studied in E-GEOD-18105

molecular subtype
studied in E-GEOD-21653

observation
studied in E-TABM-276

organism
studied in E-TABM-84

organism status
studied in E-GEOD-19188

phenotype
studied in E-GEOD-26495, E-GEOD-17636, E-GEOD-26541

population
studied in E-GEOD-4922

progesterone receptor status
studied in E-GEOD-6532

protocol type
studied in E-GEOD-22097, E-GEOD-19249, E-GEOD-19246, E-GEOD-15543

pt
studied in E-GEOD-21653

read length
studied in E-GEOD-30222

rna integrity
studied in E-TABM-325

sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampling time point
studied in E-GEOD-19743, E-MTAB-798, E-GEOD-18995

sex
studied in E-GEOD-1643, E-GEOD-7307

stimulus
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-22103

survival time
studied in E-GEOD-19188

test result
studied in E-TABM-276

transfection
studied in E-GEOD-14680

treatment
studied in E-GEOD-30501, E-GEOD-34055, E-GEOD-16837, E-GEOD-34635, E-GEOD-19246, ... (6 experiments)

tumor grading
studied in E-GEOD-4290, E-GEOD-4271

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.814 secs.
 
Gene Expression Atlas 2.0.13- 4/23/12 11:55:46 AM